首页> 外文期刊>Hepato-gastroenterology. >Comparative analysis of prognostic significance of molecular markers of apoptosis with clinical stage and tumor differentiation in patients with colorectal cancer: a single institute experience.
【24h】

Comparative analysis of prognostic significance of molecular markers of apoptosis with clinical stage and tumor differentiation in patients with colorectal cancer: a single institute experience.

机译:大肠癌患者细胞凋亡分子标记物与临床分期和肿瘤分化的预后意义的比较分析:单一机构的经验。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND/AIMS: The most important parameter determining the outcome of colorectal cancer (CRC) is the presence of metastases, which occur in 45-50% of all cases. The balance between proliferation and apoptosis is a key factor for tumor growth, and thus--for metastasis. Evaluation of markers for proliferation and apoptosis could therefore be helpful in predicting tumor behavior in early stage of carcinogenesis. METHODOLOGY: Seventy-two biopsies from cases of colorectal cancer (CRC) were immunostained for the proliferation/apoptosis-related proteins Bcl-2, Bax and p53. The resected specimens were also subjected for routine pathologic assessment as part of Tumor, Node and Metastases (TNM) staging. RESULTS: Comparing the marker protein expression with standard prognostic factors such as clinical stage and grade of differentiation revealed a lack of correlation between markers and standard prognostic factors in cases where clinical stage favors good prognosis (I and II stage). We found lack of correlationin 52% of diagnosed patients by tumor grade and 46% in patients by clinical stage. CONCLUSIONS: Co-expression of Bax with p53 protein is associated with poor clinical outcome, especially in cases without concomitant expression of bcl-2. The blocked apoptosis and inability of the organism to "liquidate" the neoplastic transformation of the cell (loss/mutation of p53), which we establish in our study in the half the patients with high and moderately differentiated carcinoma and separately in 46% of the patients with favorable prognosis by clinical stage is a reason for fast progression, too. The presence of a low correlation between the staging and the results of the molecular profiling suggest that the staging system needs to improve to address more precisely the issues of therapeutic options and patient survival. Using a panel of markers rather than a single marker is a step in this direction.
机译:背景/目的:决定结直肠癌(CRC)结局的最重要参数是转移的存在,其发生在所有病例中的45-50%。增殖与凋亡之间的平衡是肿瘤生长以及转移的关键因素。因此,对于增殖和凋亡标记的评估可能有助于预测癌变早期的肿瘤行为。方法:对来自结直肠癌(CRC)病例的72份活检组织进行了免疫染色,以检测与增殖/凋亡相关的蛋白Bcl-2,Bax和p53。作为肿瘤,淋巴结转移(TNM)分期的一部分,切除的标本也接受了常规病理评估。结果:将标志物蛋白表达与标准预后因素(例如临床阶段和分化程度)进行比较,发现在临床阶段有利于良好预后(I和II期)的情况下,标志物与标准预后因素之间缺乏相关性。我们发现,在52%的肿瘤分级患者和46%的临床分期患者中,缺乏相关性。结论:Bax与p53蛋白的共表达与临床预后不良有关,特别是在没有同时表达bcl-2的情况下。阻断的细胞凋亡和生物体无法“清除”细胞的肿瘤转化(p53的丢失/突变),这是我们在研究中确定的一半患有高分化和中度分化癌的患者,分别占46%临床阶段预后良好的患者也是进展迅速的原因。分期与分子谱分析结果之间存在低相关性,表明分期系统需要改进以更准确地解决治疗选择和患者生存的问题。使用一组标记而不是单个标记是朝这个方向迈出的一步。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号